Cellectar Biosciences, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 6,860 5,123 3,599 2,984
Sales, General and Admin. 4,445 3,632 2,692 1,157
Non-Recurring Items 1,097 - 746 53
Other - - - -
Operating Income (12,402) (8,755) (7,038) (4,194)
Income From Continuing Operations
Add'l Income/Expense Items 1,629 (34) 32 200
Earnings Before Interest and Tax (10,773) (8,789) (7,005) (3,994)
Interest Expense 9 8 430 566
Earnings Before Tax (10,782) (8,797) (7,435) (4,560)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (10,782) (8,797) (7,435) (4,560)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (10,782) (8,797) (7,435) (4,560)
Preferred Stock and Other Adjustments - (543) - -
Net Income Applicable to Common Shareholders (10,782) (9,340) (7,435) (4,560)